Drugs / Quabodepistat
Quabodepistat
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07314320 | Nov → Dec 2023 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07542847 | Sep → Nov 2022 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03678688 | Oct 2018 → Feb 2022 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | Missed primary |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT07773610 | Sep 2026 → Dec 2027 expected | pulmonary tuberculosis | TASK Applied Science | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06114628 | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT05971602 | Jul 2023 → Feb 2025 | pulmonary tuberculosis | Gates Medical Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT05221502 | Apr 2022 → Apr 2024 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07209761 | Oct 2025 → May 2027 expected | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-03-22 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment otsuka.co.jp ↗
These results show that sputum culture conversion rates -- or effectiveness of the treatment combination in killing the bacteria -- at the end of treatment in the pooled QBS-based, three-drug regimen arms were on par with existing standard four-drug TB treatment. |
| 2024-03-21 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment otsuka-us.com ↗
These results show that sputum culture conversion rates — or effectiveness of the treatment combination in killing the bacteria — at the end of treatment in the pooled QBS-based, three-drug regimen arms were on par with existing standard four-drug TB treatment. |
All press releases naming this drug 8 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quabodepistat | “Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label,...” PMID 38243296 ↗ Jan 20244“Quabodepistat (formerly OPC-167832) showed potent activity in preclinical studies and in the first stage of an early bactericidal activity study in adults with smear-positive,...” PMID 39612928 ↗ Nov 2024 “Bedaquiline 400 mg once daily for 2 weeks then 100 mg once daily for 15 weeks + Pretomanid 200 mg QD for 17 weeks + Quabodepistat 30 mg once daily for 17 weeks + Moxifloxacin...” NCT07209761 ↗ |
| Known as | OPC-167832 | “Quabodepistat (formerly OPC-167832) showed potent activity in preclinical studies and in the first stage of an early bactericidal activity study in adults with smear-positive,...” PMID 39612928 ↗ Nov 2024 |
| Known as | QBS | “Quabodepistat (QBS) is a newly discovered inhibitor of decaprenylphosphoryl-β-D-ribose-2'-oxidase, an essential enzyme for Mycobacterium tuberculosis to synthesize key...” PMID 38243296 ↗ Jan 2024 |
| Action | Inhibit | “inhibitor of decaprenylphosphoryl-β-D-ribose-2'-oxidase” PMID 38243296 ↗ Jan 2024 |
| Modality | Small molecule | — CHEMBL5095080 ↗ |
| Route | Oral | “This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive,...” NCT03678688 ↗ |